Foster Victor Wealth Advisors LLC Purchases 3,062 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Foster Victor Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,588 shares of the pharmaceutical company's stock after purchasing an additional 3,062 shares during the quarter. Foster Victor Wealth Advisors LLC's holdings in Vertex Pharmaceuticals were worth $10,376,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of VRTX. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals during the third quarter worth about $25,000. Highline Wealth Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $27,000. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Stifel Nicolaus upped their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a "hold" rating in a research note on Monday, December 16th. Morgan Stanley upped their target price on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. Raymond James reiterated a "market perform" rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Finally, Jefferies Financial Group upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and upped their target price for the company from $500.00 to $550.00 in a report on Monday, December 9th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $494.76.

Vertex Pharmaceuticals Stock Up 0.2 %

NASDAQ VRTX traded up $0.84 on Wednesday, reaching $441.52. The company had a trading volume of 1,025,800 shares, compared to its average volume of 1,495,690. The stock has a market capitalization of $113.70 billion, a P/E ratio of -221.87, a P/E/G ratio of 2.20 and a beta of 0.40. The company's fifty day moving average is $434.75 and its 200 day moving average is $463.64. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.